Cargando…

Ethical and legal issues in psychedelic harm reduction and integration therapy

Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilecki, Brian, Luoma, Jason B., Bathje, Geoff J., Rhea, Joseph, Narloch, Vilmarie Fraguada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028769/
https://www.ncbi.nlm.nih.gov/pubmed/33827588
http://dx.doi.org/10.1186/s12954-021-00489-1
_version_ 1783676003057401856
author Pilecki, Brian
Luoma, Jason B.
Bathje, Geoff J.
Rhea, Joseph
Narloch, Vilmarie Fraguada
author_facet Pilecki, Brian
Luoma, Jason B.
Bathje, Geoff J.
Rhea, Joseph
Narloch, Vilmarie Fraguada
author_sort Pilecki, Brian
collection PubMed
description Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.
format Online
Article
Text
id pubmed-8028769
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80287692021-04-08 Ethical and legal issues in psychedelic harm reduction and integration therapy Pilecki, Brian Luoma, Jason B. Bathje, Geoff J. Rhea, Joseph Narloch, Vilmarie Fraguada Harm Reduct J Opinion Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed. BioMed Central 2021-04-07 /pmc/articles/PMC8028769/ /pubmed/33827588 http://dx.doi.org/10.1186/s12954-021-00489-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Opinion
Pilecki, Brian
Luoma, Jason B.
Bathje, Geoff J.
Rhea, Joseph
Narloch, Vilmarie Fraguada
Ethical and legal issues in psychedelic harm reduction and integration therapy
title Ethical and legal issues in psychedelic harm reduction and integration therapy
title_full Ethical and legal issues in psychedelic harm reduction and integration therapy
title_fullStr Ethical and legal issues in psychedelic harm reduction and integration therapy
title_full_unstemmed Ethical and legal issues in psychedelic harm reduction and integration therapy
title_short Ethical and legal issues in psychedelic harm reduction and integration therapy
title_sort ethical and legal issues in psychedelic harm reduction and integration therapy
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028769/
https://www.ncbi.nlm.nih.gov/pubmed/33827588
http://dx.doi.org/10.1186/s12954-021-00489-1
work_keys_str_mv AT pileckibrian ethicalandlegalissuesinpsychedelicharmreductionandintegrationtherapy
AT luomajasonb ethicalandlegalissuesinpsychedelicharmreductionandintegrationtherapy
AT bathjegeoffj ethicalandlegalissuesinpsychedelicharmreductionandintegrationtherapy
AT rheajoseph ethicalandlegalissuesinpsychedelicharmreductionandintegrationtherapy
AT narlochvilmariefraguada ethicalandlegalissuesinpsychedelicharmreductionandintegrationtherapy